Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Gains from Investment Securities (2016 - 2026)

Ocular Therapeutix has reported Gains from Investment Securities over the past 14 years, most recently at $419676.0 for Q1 2026.

  • For Q1 2026, Gains from Investment Securities fell 59.98% year-over-year to $419676.0; the TTM value through Mar 2026 reached $419676.0, down 59.98%, while the annual FY2025 figure was $1.7 million, 91.58% down from the prior year.
  • Gains from Investment Securities for Q1 2026 was $419676.0 at Ocular Therapeutix, down from $18.3 million in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $19.9 million in Q4 2024 and troughed at $1000.0 in Q1 2023.
  • A 5-year average of $3.2 million and a median of $862839.5 in 2024 define the central range for Gains from Investment Securities.
  • Biggest five-year swings in Gains from Investment Securities: plummeted 99.96% in 2023 and later skyrocketed 99309.9% in 2024.
  • Year by year, Gains from Investment Securities stood at $212150.0 in 2022, then rose by 29.15% to $274000.0 in 2023, then surged by 7158.28% to $19.9 million in 2024, then fell by 7.74% to $18.3 million in 2025, then crashed by 97.71% to $419676.0 in 2026.
  • Business Quant data shows Gains from Investment Securities for OCUL at $419676.0 in Q1 2026, $18.3 million in Q4 2025, and $262429.0 in Q3 2025.